Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:LNTH NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.04+1.0%$3.90$1.72▼$8.21$512.26M2.083.23 million shs2.92 million shsEDITEditas Medicine$2.46-1.6%$2.95$1.66▼$4.54$244.77M2.163.26 million shs2.46 million shsLNTHLantheus$104.67+0.1%$91.25$47.25▼$104.99$6.80B-0.03999,337 shs798,589 shsSRPTSarepta Therapeutics$15.77+3.0%$19.08$10.41▼$25.32$1.62B0.212.64 million shs2.31 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%+0.33%-16.62%-55.41%+9.45%EDITEditas Medicine0.00%-7.75%-4.58%-1.57%+26.90%LNTHLantheus0.00%+3.51%+11.30%+33.15%+34.29%SRPTSarepta Therapeutics0.00%-2.79%-12.76%-8.10%-57.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.04+1.0%$3.90$1.72▼$8.21$512.26M2.083.23 million shs2.92 million shsEDITEditas Medicine$2.46-1.6%$2.95$1.66▼$4.54$244.77M2.163.26 million shs2.46 million shsLNTHLantheus$104.67+0.1%$91.25$47.25▼$104.99$6.80B-0.03999,337 shs798,589 shsSRPTSarepta Therapeutics$15.77+3.0%$19.08$10.41▼$25.32$1.62B0.212.64 million shs2.31 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%+0.33%-16.62%-55.41%+9.45%EDITEditas Medicine0.00%-7.75%-4.58%-1.57%+26.90%LNTHLantheus0.00%+3.51%+11.30%+33.15%+34.29%SRPTSarepta Therapeutics0.00%-2.79%-12.76%-8.10%-57.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.91Moderate Buy$12.10298.03% UpsideEDITEditas Medicine 2.57Moderate Buy$5.40119.51% UpsideLNTHLantheus 2.73Moderate Buy$101.86-2.69% DownsideSRPTSarepta Therapeutics 2.07Hold$24.7757.09% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M6.79N/AN/A$0.58 per share5.24EDITEditas Medicine$40.52M5.94N/AN/A$0.28 per share8.79LNTHLantheus$1.54B4.42$6.39 per share16.37$16.43 per share6.37SRPTSarepta Therapeutics$2.18B0.76N/AN/A$10.89 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)LNTHLantheus$233.56M$4.1525.2219.38N/A18.05%29.32%15.00%8/5/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A6.070.16-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, CTMX, EDIT, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A10.3810.38EDITEditas MedicineN/A3.223.22LNTHLantheus0.472.832.64SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%LNTHLantheus99.06%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics3.80%EDITEditas Medicine3.10%LNTHLantheus1.70%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, CTMX, EDIT, and LNTH HeadlinesRecent News About These CompaniesING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPTJune 10, 2026 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Hold" from BrokeragesJune 10, 2026 | americanbankingnews.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | finance.yahoo.comIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?June 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | finance.yahoo.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | zacks.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | zacks.comBioGene Therapeutics Inc. Appoints Ty Howton to Board of DirectorsJune 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial MarketsJune 7, 2026 | marketbeat.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | finance.yahoo.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | insidermonkey.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | finance.yahoo.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | zacks.comSarepta Shareholders Approve 2026 Equity and ESPP PlansJune 4, 2026 | tipranks.comSRPT Expands Into Huntington’s Disease With New First-in-Human TrialJune 4, 2026 | tipranks.comSarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call TranscriptJune 4, 2026 | seekingalpha.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | finance.yahoo.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | businesswire.comIn Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 PrioritiesMay 27, 2026 | finance.yahoo.comAssessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price WeaknessMay 26, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor TestBy Jessica Mitacek | June 6, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026SRPT, CTMX, EDIT, and LNTH Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.04 +0.03 (+1.00%) Closing price 04:00 PM EasternExtended Trading$3.06 +0.02 (+0.66%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.46 -0.04 (-1.60%) Closing price 04:00 PM EasternExtended Trading$2.49 +0.03 (+1.06%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Lantheus NASDAQ:LNTH$104.67 +0.15 (+0.14%) Closing price 04:00 PM EasternExtended Trading$104.73 +0.06 (+0.06%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$15.77 +0.46 (+3.00%) Closing price 04:00 PM EasternExtended Trading$15.80 +0.04 (+0.22%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
